Marrubium Vulgare Whole

Dosage for Marrubium Vulgare Whole is highly individualized and must be determined by an allergist based on the patient's skin test sensitivity and clinical history. There is no 'standard' dose for non-standardized extracts.

Diagnostic Dosing

• Prick/Puncture Test: One drop of the concentrate (typically 1:10 or 1:20 w/v) is applied to the skin, followed by a puncture through the drop. Results are read at 15–20 minutes.
• Intradermal Test: 0.02 mL to 0.05 mL of a highly dilute solution (e.g., 1:1000 w/v) is injected into the dermis.

Immunotherapy Dosing (SCIT)

Immunotherapy follows a two-phase schedule:

1. 1Build-up Phase: Injections are given 1–2 times per week. The starting dose is usually 0.05 mL of a very dilute solution (e.g., 1:100,000 w/v). The dose is increased incrementally (e.g., 0.1 mL, 0.2 mL, 0.4 mL) until the maintenance concentration is reached.
2. 2Maintenance Phase: Once the 'top dose' is reached (often 0.5 mL of a 1:100 or 1:20 w/v solution), the frequency of injections is decreased to once every 2–4 weeks.

Marrubium Vulgare Whole may be used in children, typically those aged 5 years and older. Dosing principles are identical to adult dosing; however, smaller volumes may be used initially to assess tolerance. Children must be closely monitored for systemic reactions, as they may have more difficulty communicating early symptoms of anaphylaxis.

Renal Impairment

No specific dose adjustments are required for renal impairment, as the extract is not cleared primarily by the kidneys in a way that affects toxicity. However, patients with severe renal disease should be evaluated for their ability to tolerate emergency medications (like epinephrine) if a reaction occurs.

Hepatic Impairment

No dosage adjustments are provided for hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The dose may be increased more slowly during the build-up phase to minimize the risk of systemic reactions that could stress the heart.

• Professional Administration Only: This medication is never self-administered at home. It must be given in a clinical setting equipped with oxygen, epinephrine, and airway management tools.
• Injection Site: Immunotherapy injections are given subcutaneously in the posterior aspect of the upper arm.
• Observation Period: Patients MUST remain in the doctor's office for at least 30 minutes after every injection to monitor for signs of anaphylaxis.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Freezing can denature the allergenic proteins, rendering the extract ineffective or potentially dangerous.

If an immunotherapy dose is missed, the next dose may need to be reduced depending on how much time has passed:

• 1–2 weeks late: The previous dose may be repeated.
• 3–4 weeks late: The dose is typically reduced by one or two increments.
• Over 4 weeks late: The physician may require restarting the build-up from a much lower concentration to ensure safety.

An overdose in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level. This can occur due to a calculation error or a rapid increase in the build-up phase.

• Signs of Overdose: Rapid onset of hives (urticaria), swelling of the throat (angioedema), wheezing, drop in blood pressure, or loss of consciousness.
• Emergency Measures: Immediate administration of intramuscular epinephrine, followed by antihistamines, corticosteroids, and IV fluids. Emergency medical services (EMS) must be contacted immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients undergoing testing or treatment with Marrubium Vulgare Whole will experience local reactions. These are generally considered normal and expected.

• Local Wheal and Flare: During skin testing, a small, itchy bump (wheal) and surrounding redness (flare) are the intended results. This usually resolves within 1–2 hours.
• Injection Site Swelling: In immunotherapy, swelling at the site of the injection (up to the size of a half-dollar) is common. This may feel warm, itchy, or slightly tender.
• Erythema: Redness at the injection site that may persist for 24 hours.

• Large Local Reactions (LLR): Swelling that exceeds 5–10 cm in diameter. While not dangerous, an LLR often requires a dosage adjustment for the next injection.
• Fatigue: Some patients report feeling unusually tired for a few hours following an immunotherapy session.
• Mild Nasal Congestion: A slight increase in hay fever symptoms immediately following the injection.

• Generalized Urticaria: Hives appearing on parts of the body far from the injection site.
• Persistent Pruritus: Intense itching that lasts for several days.
• Vasovagal Syncope: Fainting due to the needle stick or anxiety, rather than a reaction to the extract itself.

> Warning: Stop taking Marrubium Vulgare Whole and call your doctor immediately if you experience any of these symptoms, which may indicate the onset of anaphylaxis.

• Respiratory Distress: Difficulty breathing, shortness of breath, or a feeling of 'tightness' in the chest.
• Laryngeal Edema: A 'lump' in the throat, hoarseness, or difficulty swallowing.
• Hypotension: Feeling lightheaded, dizzy, or fainting (signs of a dangerous drop in blood pressure).
• Angioedema: Significant swelling of the lips, tongue, or face.
• Tachycardia: A rapid or pounding heartbeat.
• Cyanosis: A bluish tint to the lips or fingernails, indicating low oxygen levels.

There are no known long-term 'toxic' effects of Marrubium Vulgare Whole when used correctly. The primary long-term outcome is the intended modification of the immune system. However, patients should be aware that:

• Persistent Sensitization: In rare cases, skin testing could theoretically induce a new sensitivity, although this is clinically uncommon with modern extracts.
• Nodule Formation: Rarely, a small, hard lump (granuloma) may form under the skin at the site of repeated injections.

WARNING: RISK OF SEVERE ALLERGIC REACTION

• Marrubium Vulgare Whole allergenic extract can cause severe, life-threatening systemic reactions, including anaphylaxis.
• This product must only be administered by healthcare providers prepared to manage anaphylaxis.
• Patients must be observed for at least 30 minutes following administration.
• Patients with unstable or severe asthma are at increased risk for fatal reactions.
• This product may not be suitable for patients taking beta-blockers, as these medications can interfere with the effectiveness of epinephrine used to treat a reaction.

Report any unusual symptoms to your healthcare provider. Even a 'mild' systemic reaction (like a few hives) must be reported, as it may precede a more severe reaction at the next dose.

Marrubium Vulgare Whole is a potent biological substance. Its use is restricted to clinical environments where emergency resuscitation is possible. Patients must be in their 'baseline' state of health before receiving an injection; for example, an injection should be postponed if the patient is experiencing an acute asthma flare or a high fever.

No FDA black box warnings for Marrubium Vulgare Whole specifically, but all non-standardized allergenic extracts carry a class-wide warning regarding the risk of Anaphylaxis. The labeling emphasizes that systemic reactions can occur at any time, even in patients who have previously tolerated the extract for years. Fatalities have occurred with allergenic extracts; these are most commonly associated with errors in dosing or administration to patients with poorly controlled asthma.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Anaphylaxis can progress within seconds. Patients must be educated on the use of an epinephrine auto-injector (e.g., EpiPen) if a delayed reaction occurs after they leave the clinic.
• Asthma Status: Patients with symptomatic asthma or significantly reduced FEV1 (forced expiratory volume) should not receive immunotherapy until their asthma is stabilized. Asthma is the single greatest risk factor for a fatal reaction to allergy shots.
• Cardiovascular Disease: Patients with a history of myocardial infarction, unstable angina, or significant arrhythmias may not tolerate the physiological stress of a systemic reaction or the epinephrine required to treat it.
• Autoimmune Disorders: Caution is advised in patients with active autoimmune diseases (like SLE or Rheumatoid Arthritis), as immunotherapy theoretically could exacerbate these conditions, though data is limited.

• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before each injection to ensure their lung function is stable.
• Vital Signs: Blood pressure and heart rate may be checked if the patient feels unwell.
• Skin Site Observation: The clinician will measure any local swelling at 30 minutes and record it to guide future dosing.

Marrubium Vulgare Whole does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

There is no direct chemical interaction between alcohol and Marrubium Vulgare Whole. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption or mask early symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours before and after an injection.

Immunotherapy is typically a 3-to-5-year commitment. Stopping prematurely usually results in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping Marrubium Vulgare Whole, but the therapeutic benefits will gradually diminish over time if the course is not completed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Marrubium Vulgare Whole.

• Beta-Blockers (Non-selective and Selective): Drugs like propranolol, metoprolol, or atenolol are generally contraindicated during immunotherapy. Clinical Consequence: Beta-blockers can increase the severity of anaphylaxis and, more importantly, they block the effects of epinephrine (adrenaline). If a patient on a beta-blocker has a severe reaction, the standard life-saving treatment may fail. Management: Patients must be switched to an alternative antihypertensive class (like ACE inhibitors or CCBs) before starting immunotherapy.

• MAO Inhibitors (MAOIs): Drugs like phenelzine or selegiline. Mechanism: MAOIs can potentiate the effects of pressor amines. Clinical Consequence: This can complicate the management of a systemic reaction if epinephrine is administered, potentially leading to a hypertensive crisis.
• Tricyclic Antidepressants (TCAs): Drugs like amitriptyline. Similar to MAOIs, these can increase the heart's sensitivity to epinephrine, making the treatment of anaphylaxis more dangerous.

• Antihistamines (H1-antagonists): Drugs like loratadine (Claritin), cetirizine (Zyrtec), or diphenhydramine (Benadryl). Mechanism: These drugs block the H1 receptors that produce the wheal and flare reaction. Clinical Consequence: Antihistamines will cause a false-negative result on diagnostic skin tests. Management: Patients must stop taking antihistamines for 3 to 7 days before skin testing.
• H2-Blockers: Drugs like famotidine (Pepcid). These can also mildly suppress skin test reactivity and should be discontinued 48 hours before testing.

There are no specific food interactions with Marrubium Vulgare Whole. However, patients with a 'Mint family' allergy should be cautious of cross-reactive foods, though this is rare. High-protein meals or heavy exercise immediately after an injection should be avoided, as they increase systemic circulation and may hasten allergen absorption.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat anaphylaxis, though this is not clinically well-documented.
• Herbal Antihistamines: Supplements like Butterbur or high-dose Quercetin may suppress skin test results and should be disclosed to the allergist.

• Skin Prick Testing: As noted, medications can interfere with the results.
• Total IgE Levels: Immunotherapy may cause a transient rise in total IgE levels early in treatment, followed by a long-term decline. This is an expected physiological response and not a sign of 'toxicity.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted or those with recent hospitalizations for asthma. Mechanism: These patients have no 'pulmonary reserve.' A minor systemic reaction could trigger a fatal bronchospasm.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3–6 months. Mechanism: The heart is too fragile to handle the potential stress of anaphylaxis or the high doses of epinephrine required to treat it.
3. 3History of Severe Anaphylaxis to this Specific Extract: If a patient has previously had a near-fatal reaction to Marrubium Vulgare Whole, the risks of continuing immunotherapy usually outweigh the benefits.
4. 4Beta-Blocker Therapy: As described in the interactions section, the inability to respond to epinephrine is an absolute contraindication in many clinical guidelines.

1. 1Pregnancy: While immunotherapy is usually not started during pregnancy due to the risk of anaphylaxis to the fetus, it is often continued at a stable maintenance dose if the patient is already tolerating it.
2. 2Autoimmune Disease: Patients with Sjögren's syndrome, Myasthenia Gravis, or other active autoimmune disorders require a careful risk-benefit analysis.
3. 3Malignancy: Patients undergoing active chemotherapy or radiation may have unpredictable immune responses.
4. 4Very Young Children (under 5): Due to the difficulty in monitoring for subjective symptoms of a reaction.

Marrubium Vulgare is in the Lamiaceae family. Patients who are highly allergic to other members of this family—such as Mint, Oregano, Basil, Lavender, or Sage—may show cross-reactivity on skin tests. This does not necessarily mean they cannot take the extract, but the clinician should be aware of the potential for increased sensitivity.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Marrubium Vulgare Whole.

• FDA Category C: Animal reproduction studies have not been conducted with Marrubium Vulgare Whole. It is not known whether the extract can cause fetal harm.
• Risks: The primary risk during pregnancy is not the extract itself, but the potential for maternal anaphylaxis. Anaphylaxis causes a sudden drop in maternal blood pressure, which can lead to fetal hypoxia (lack of oxygen), permanent brain damage, or fetal death.
• Clinical Practice: Allergists generally do not initiate the 'build-up' phase in pregnant women. If a woman is already on a stable maintenance dose and doing well, the treatment is usually continued at that same dose without further increases.

It is not known if the allergenic proteins in Marrubium Vulgare Whole are excreted in human milk. However, because these are large proteins that are likely broken down in the mother's lymphatic system, the risk to a nursing infant is considered negligible. Immunotherapy is generally considered safe for breastfeeding mothers.

• Safety: Immunotherapy is effective in children for preventing the 'allergic march' (the progression from hay fever to asthma).
• Dosing: Children receive the same concentrations as adults, but the volume may be adjusted.
• Considerations: Clinicians must ensure the child is old enough to cooperate with the 30-minute observation period and can describe symptoms like an 'itchy throat' or 'funny feeling.'

• Cardiovascular Risk: Patients over 65 are more likely to have underlying heart disease. The risk of using epinephrine in this population (which can cause arrhythmias or heart strain) must be weighed against the benefit of the allergy treatment.
• Renal Function: While renal clearance is not a major factor for the extract, it may affect the clearance of other medications used to manage reactions.

No specific studies have been conducted in patients with renal impairment. Because the extract is a biological protein administered in minute quantities, it is unlikely to require dose adjustment for kidney disease. However, these patients should be monitored for their ability to handle the fluid shifts associated with severe allergic reactions.

There are no known issues with Marrubium Vulgare Whole in patients with liver disease. The liver is not involved in the primary immunological mechanism of action.

> Important: Special populations require individualized medical assessment.

Marrubium Vulgare Whole acts as an exogenous antigen. Upon subcutaneous administration, the extract's proteins are captured by Dendritic Cells (antigen-presenting cells). These cells migrate to the lymph nodes and present the plant peptides to Naive T-cells. In a successful immunotherapy course, this presentation leads to the expansion of T-regulatory (Treg) cells. These Tregs produce Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β), which signal B-cells to switch production from IgE (the allergy antibody) to IgG4 (the protective antibody). IgG4 acts as a 'decoy,' binding to the White Horehound pollen proteins before they can reach the IgE on mast cells.

• Onset of Action: For diagnostic testing, the onset is 15–20 minutes. For immunotherapy, clinical improvement typically takes 3–6 months of consistent build-up.
• Duration of Effect: A completed 3-to-5-year course of immunotherapy can provide 'permanent' or long-lasting relief (years to decades) by fundamentally altering the immune system's memory.
• Dose-Response: There is a clear dose-response relationship; higher maintenance doses are generally more effective but carry a higher risk of systemic side effects.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Epicutaneous) |

| Protein Binding | N/A (Interaction with IgE/IgG4) |

| Half-life | Variable (Proteins degraded within hours/days) |

| Tmax | 15-30 minutes (Local) |

| Metabolism | Proteolysis by cellular enzymes |

| Excretion | Renal (as small peptides) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides derived from the Marrubium vulgare plant.
• Solubility: Soluble in aqueous buffers; often provided in a 50% glycerin/water solution for stability.
• Molecular Weight: Ranges from 10 kDa to over 100 kDa for various allergenic fractions.

Marrubium Vulgare Whole is a Non-Standardized Plant Allergenic Extract. It is grouped with other weed and herb extracts like Ragweed (though Ragweed is often standardized) and Sagebrush. Its primary therapeutic area is Clinical Immunology and Allergy.